Conclusions-A substantial number of coronary arteries with stenoses showing an FFR>0.80 present disturbed hemodynamics. Integration of FFR, CFR, and IMR supports the existence of differentiated patterns of ischemic heart disease that combine focal and diffuse coronary narrowings with variable degrees of MCD. 2
Summary-Evidence from prospective epidemiological studies has accumulated to firmly document an association of elevated circulating levels of lipoprotein(a) (Lp(a)) with cardiovascular disease (CVD) including coronary artery disease, cerebrovascular disease, and peripheral artery disease. Lipoprotein apheresis can lower low-density lipoprotein cholesterol and Lp(a) and is the final escalating option in severely hypercholesterolemic patients, including genetic or other forms of hypercholesterolemia resistant to or intolerant of the use of statins or combined lipidlowering medication. The major effect of lipoprotein apheresis is the prevention of cardiovascular events. The Pro(a)LiFe study showed that commencing chronic lipoprotein apheresis could reduce the incidence rate of cardiovascular events in patients with Lp(a)-hyperlipoproteinemia and progressive CVD that persisted despite the maximal treatment of other concomitant cardiovascular risk factors. Results of this prospective study support the hypothesis that Lp(a) might be a causal factor for progression of CVD in patients with Lp(a)-hyperlipoproteinemia. Efforts must be made to identify these patients to optimize their treatment including multimodality approaches. The assessment of cardiovascular risk, in particular, for patients who are already at high risk owing to established CVD should include measurement of Lp(a). Lp(a) levels are generally not influenced by lifestyle. A widely useable substance for effective pharmacological lowering of Lp(a) is not yet available. Nicotinic acid at high doses has shown a Lp(a)-lowering effect in clinical practice. Limited by side effects, the use of nicotinic acid has not seen wide application. In Europe, nicotinic acid is no longer available. Lipoprotein apheresis can be regarded as a reasonable and available therapeutic option for high-risk patients with Lp(a)-hyperlipoproteinemia and progressive CVD.
Conclusions-In patients with Lp(a)-hyperlipoproteinemia, progressive cardiovascular disease, and maximally tolerated lipid-lowering medication, LA effectively lowered the incidence rate of cardiovascular events. 1
Disturbed Coronary Hemodynamics in Vessels With Intermediate Stenoses Evaluated With Fractional Flow Reserve: A Combined Analysis of Epicardial and Microcirculatory Involvement in Ischemic Heart Disease
Summary-Although impairment of myocardial blood supply in ischemic heart disease results from both obstructive and nonobstructive coronary involvement, its diagnosis is largely stenosis-centred. Fractional flow reserve (FFR) informs on whether treating epicardial stenoses may benefit the patient, but not on whether concomitant nonobstructive coronary disease, which might also influence outcome, is present. To investigate this, a comprehensive assessment of coronary hemodynamics with FFR (abnormal ≤0.80), coronary flow reserve (CFR, abnormal <2.0), and microcirculatory resistance (IMR) was performed in 93 vessels with intermediate stenoses. Interestingly, 63% of vessels with normal FFR>0.80 presented disturbed hemodynamics, revealed by abnormal CFR (52%) or microcirculatory disease (MCD, defined as IMR≥29.1) (33%). Indeed, and as theoretically expected, the presence of MCD almost invariably implied nonsignificant (>0.80) FFR values that could be wrongly interpreted as absence of significant disease. Four coronary hemodynamic patterns were generated based on dichotomous classification of FFR and CFR; nonagreement groups (accounting for 63% of vessels) seem to result from the presence of diffuse epicardial disease (CFR≤2.0 and FFR>0.80) or from focal epicardial narrowing with preserved microcirculatory function (FFR≤0.80 and preserved CFR>2.0). Future research should address whether if the first group might have a worse prognosis despite an FFR >0.80, whereas in the latter revascularization might be spared despite an FFR≤0.80 (as a result of preserved CFR). Overall, the observations serve as a preamble to a more comprehensive, yet required, intracoronary assessment of ischemic heart disease, which may improve prognostic characterization and guide therapeutic strategies aiming to both obstructive and nonobstructive coronary disease.
Summary-Smooth muscle cells (SMCs) critically influence the clinical course of vascular disease. The close regulation of SMC migration and proliferation within the intimal space is critical in maintaining a delicate balance between insufficient and excessive atherosclerotic plaque repair. When SMC proliferation is too suppressed, the ensuing weakening of the fibrous cap can result in the plaque vulnerability that underlies acute coronary syndrome, and when SMC proliferation is excessive, intimal hyperplasia can follow, such as in restenosis after percutaneous coronary intervention. Although stents have vastly improved on the recoil and constrictive remodeling component of restenosis, the problem of accelerated intimal SMC growth has remained. The current approach of delivering stents that release nonspecific agents that promote cell death or inhibition of proliferation has been successful in reducing the need for recurrent vascular interventions; however, this success comes at the expense of delaying vascular healing, the ultimate long-term clinical impact of which is still being evaluated. Short-and long-term negative effects on the healing arterial wall, such as delayed reendothelialization, increased inflammation, and enhanced thrombogenicity, are undisputed. These side effects of drug-eluting stents are being masked by prolonged and aggressive antiplatelet therapy, which exposes patients, especially the elderly, to increased bleeding risks, complicates clinical decision making through fear of too early treatment cessation, demands rigorous patient compliance, and is costly. These issues are not trivial in daily clinical practice. The possible role of podocan as a novel selective inhibitor of the SMC response and the Wnt-TCF pathway opens the door to modulation of vascular SMCs in a smarter and more physiological way.
Conclusions-Podocan appears to be a potent negative regulator of the migration and proliferation of both murine and human SMCs. The lack of podocan results in excessive arterial repair and prolonged SMC proliferation, which likely is mediated by the Wnt-TCF pathway. 3
Impaired Cholesterol Metabolism and Enhanced Atherosclerosis in Clock Mutant Mice
Summary-Heart attacks happen mainly in the early hours of the day, suggesting that their occurrence might be related to circadian rhythms seen in various behavioral, physiological, and biochemical activities.
Here, we show that disruption of circadian Clock activity as a result of a dominant-negative mutation (Clock Δ19/Δ19 ) increases susceptibility to atherosclerosis in various mouse models. ClockΔ19/Δ19 mice fed an atherogenic diet had increased plasma cholesterol, triglycerides, and atherosclerotic lesions compared with their wild-type siblings. Similarly, Clock Δ19/Δ19 protein increased cholesterolemia and atherosclerosis in Ldlr −/− and Apoe −/− mice fed a chow or Western diets. Physiological studies revealed that high plasma cholesterol in ClockΔ19/Δ19Apoe −/− mice was due in part to increased cholesterol uptake by enterocytes. In addition, macrophages in ClockΔ19/Δ19Apoe −/− mice displayed higher lipid uptake and reduced cholesterol efflux compared with Apoe −/− siblings. Molecular studies demonstrated that knockdown of Clock gene expression in wild-type macrophages reduces ABCA1 expression and cholesterol efflux. Furthermore, Clock overexpression increases ABCA1 transcription. Evidence is presented to suggest that USF2 could participate in the modulatory effect of Clock on ABCA1 expression. These studies provide significant evidence for the importance of Clock in the proper physiological functioning of enterocytes and macrophages. Hence, disruptions in Clock function as a result of either mutations or other environmental factors such as a high-fat diet, transcontinental flights, and night shift work might deregulate enterocyte and macrophage function, increasing the risk for atherosclerosis.
Conclusions-Clock Δ19/Δ19 protein enhances atherosclerosis by increasing intestinal cholesterol absorption, augmenting uptake of modified lipoproteins by macrophages, and reducing cholesterol efflux from macrophages. These studies establish that circadian Clock activity is crucial in maintaining low plasma cholesterol levels and in reducing atherogenesis in mice. 4
Effect of Early Metoprolol on Infarct Size in ST-Segment-Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention: The Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) Trial
Summary-The capacity of β-blockers to reduce infarct size was evaluated extensively in the prereperfusion era with controversial results. In the context of reperfusion as the treatment of choice for ST-segment-elevation myocardial infarction (STEMI), this has been poorly investigated. Experimental data suggest that the β-blocker metoprolol is able to reduce infarct size only when administered intravenously before reperfusion. Here, we present the results of the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) trial, the first randomized, clinical trial prospectively evaluating the effect of early intravenous β-blockade on infarct size in conjunction with primary angioplasty. A total of 270 patients with anterior STEMI (Killip class II or less) revascularized within 6 hours after symptom onset were randomized to receive intravenous metoprolol or not before reperfusion. All patients received oral metoprolol according to clinical guidelines (first dose, 12-24 hours after infarction). Infarct size, evaluated by MRI and creatine kinase release, was significantly reduced in the intravenous metoprolol group with no excess side effects. Left ventricular ejection fraction was higher in the intravenous metoprolol group. This cardioprotective effect appeared to be restricted to patients with a preangioplasty Thrombolysis in Myocardial Infarction grade 0 to 1 flow. Here, we show that an inexpensive medication already approved in the context of STEMI can significantly reduce infarct size just by administering it intravenously before reperfusion in patients with no contraindications. Given the important role of final infarct size as a main determinant of long-term mortality in STEMI survivors, the possibility of applying inexpensive strategies available to a wide proportion of STEMI patients is of clinical value.
Conclusions-In patients with anterior Killip class II or less ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention, early intravenous metoprolol before reperfusion reduced infarct size and increased left ventricular ejection fraction with no excess of adverse events during the first 24 hours after STEMI. 5 ischemic heart disease, but whether both lipoproteins also are associated with low-grade inflammation is unknown. This is a clinically important question because atherosclerosis is a disease with an inflammatory component and because randomized, clinical intervention trials have shown that statins prevent cardiovascular disease in individuals with low-grade inflammation with moderately elevated levels of C-reactive protein, even when low-density lipoprotein cholesterol levels are relatively low. The reason could be that statins lower not only low-density lipoprotein cholesterol levels but also triglycerides levels and thus remnant cholesterol levels. In this study, we found both elevated levels of nonfasting remnant cholesterol and elevated levels of low-density lipoprotein cholesterol to be causally associated with increased risk of ischemic heart disease, but only elevated levels of nonfasting remnant cholesterol were causally associated with low-grade inflammation. Taken together, this suggests that elevated low-density lipoprotein cholesterol levels cause atherosclerosis without a major inflammatory component, whereas an inflammatory component of atherosclerosis is driven by elevated nonfasting remnant cholesterol levels. Thus, we here point toward a new direction for reducing cardiovascular disease beyond that achieved through low-density lipoprotein cholesterol lowering.
Conclusions-Elevated nonfasting remnant cholesterol is causally associated with low-grade inflammation and with IHD, whereas elevated LDL cholesterol is associated causally with IHD without inflammation. 6
Inhibition of MicroRNA-92a Protects Against Ischemia/Reperfusion Injury in a Large-Animal Model
Summary-Although revascularization of an infarct-related artery is state-of-the-art treatment of acute coronary syndromes, ischemia/ reperfusion induces cellular stress and damage, potentially inflicting organ dysfunction. Treatment options are required to simultaneously prevent cardiomyocyte damage, endothelial dysfunction, and overwhelming postischemic inflammation. MicroRNA (miR) inhibition might meet these requirements because miRs target multiple signaling pathways, thereby providing pleiotropic effects. miR-92a, a member of the miR17-92 cluster, is upregulated after acute myocardial infarction, and its inhibition enhanced neovascularization in a murine infarct model. Here, we demonstrate that regional miR-92a inhibition via locked nucleic acid-modified antisense miR-92a (LNA-92a) improved cardiac function and reduced ischemia/reperfusion-induced cardiomyocytic cell death, endothelial dysfunction, and inflammation. Regional application of LNA-92a might offer a novel therapeutic option to improve cardiac function after acute myocardial ischemia/reperfusion injury. Conclusions-Regional LNA-92a delivery reduces miR-92a levels and infarct size and postischemic loss of function. LNA-92a exerts cell-protective, proangiogenic, and anti-inflammatory effects. miR-92a inhibition might be a novel therapeutic tool to preserve cardiac function after ischemia. 7
Stent Thrombosis With Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes: An Analysis From the Prospective, Randomized PLATO Trial
Summary-The risk of stent thrombosis, a life-threatening complication of stent placement, is reduced by antiplatelet therapy combining aspirin and a P2Y 12 platelet receptor antagonist such as clopidogrel.
When platelet inhibition is inadequate, the risk increases. Clopidogrel produces moderate and variable P2Y 12 inhibition. Ticagrelor, a reversibly acting nonthienopyridine P2Y 12 antagonist that provides more potent and consistent platelet inhibition, was compared with clopidogrel in patients with acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial and reduced the primary outcome of cardiovascular death, myocardial infarction, and stroke, as well as cardiovascular mortality. This analysis describes the effects of ticagrelor compared with clopidogrel on the risk of stent thrombosis in patients with stents in the PLATO trial. Of 18 624 patients hospitalized for acute coronary syndromes, 61% had at least 1 intracoronary stent and were analyzed. Ticagrelor reduced definite stent thrombosis compared with clopidogrel (hazard ratio, 0.67; 95% confidence interval, 0.50-0.90; P=0.0091) but also definite or probable and any stent thrombosis. The reduction in definite stent thrombosis was consistent regardless of acute coronary syndromes type, the presence of diabetes mellitus, stent type (drug-eluting or bare metal stent), CYP2C19 genetic status, loading dose of aspirin, dose of clopidogrel before randomization, and use of glycoprotein IIb/IIIa inhibitors at randomization. Randomization to ticagrelor was a strong independent inverse predictor of definite stent thrombosis in multivariable Cox regression analyses. Ticagrelor compared with clopidogrel reduced the incidence of stent thrombosis in acute coronary syndromes patients across a broad range of patient, stent, and treatment characteristics.
Conclusions-Ticagrelor compared with clopidogrel reduces the incidence of stent thrombosis in patients with acute coronary syndromes, with consistent benefit across a broad range of patient, stent, and treatment characteristics. 8
AMG145, a Monoclonal Antibody Against Proprotein Convertase Subtilisin Kexin Type 9, Significantly Reduces Lipoprotein(a) in Hypercholesterolemic Patients Receiving Statin Therapy: An Analysis From the LDL-C Assessment With Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined With Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 Trial
Summary-Lipoprotein(a) [Lp(a)] is a circulating lipoprotein composed of an apolipoprotein B100 molecule covalently bound to a liver-derived glycoprotein, apolipoprotein(a). In epidemiological and genetic analyses, Lp(a) has emerged as an important risk factor for the development of cardiovascular disease. The 2011 European Society of Cardiology/European Atheroscloerosis Society guidelines recommend screening for elevated Lp(a) in people at high risk for cardiovascular disease or with a strong family history of premature atherothrombotic disease. There are limited therapeutic options for lowering Lp(a) levels. We sought to evaluate the impact of AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9 (PCSK9), on Lp(a) levels in the LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial, a randomized, phase 2 trial of AMG145 versus placebo. We found that compared with placebo, AMG145 significantly lowers Lp(a) in subjects with hypercholesterolemia receiving background therapy with statin with or without ezetimibe. Specifically, we observed dose-response relationships at both dosing frequencies, with progressively more robust reductions in Lp(a), up to 32%, from baseline to week 12. We found that the reduction in Lp(a) with AMG145 was consistent across several important subgroups including age, sex, race, history of diabetes mellitus, and background statin regimen. Although the clinical benefit of Lp(a) reduction remains undefined, these data lend further support to studying the impact of PCSK9 inhibition with AMG145 in a phase 3 clinical outcomes trial.
Conclusions-AMG145 significantly reduces Lp(a), by up to 32%, among subjects with hypercholesterolemia receiving statin therapy, offering an additional, complementary benefit beyond robust low-density lipoprotein cholesterol reduction with regard to a patient's atherogenic lipid profile. 9
Rosiglitazone and Outcomes for Patients With Diabetes Mellitus and Coronary Artery Disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial
Summary-Rosiglitazone is a thiazolidinedione that improves glycemic control for patients with type 2 diabetes mellitus, but there remains controversy regarding its association with increased cardiovascular hazard, and the cardiovascular effects of rosiglitazone for patients with established coronary artery disease remain unknown. The association between rosiglitazone use and cardiovascular events was examined among 2368 patients with type 2 diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial during 4.5 years of follow-up using both Cox proportional hazards models for on-treatment events and propensity-matched analyses. Among patients undergoing treatment with rosiglitazone, there was a significantly lower adjusted incidence of the composite outcome of death, myocardial infarction, and stroke, as well as of stroke, whereas the incidences of myocardial infarction, congestive heart failure, and death were not significantly different. Among propensity-matched patients, the risks of major ischemic cardiovascular events and congestive heart failure were not significantly different. There was a higher incidence of fractures observed among rosiglitazone-treated patients. An interaction was also observed between use of metformin and rosiglitazone that appeared to mitigate an increased risk of congestive heart failure with rosiglitazone. The results of these analyses from BARI 2D do not support an association of rosiglitazone treatment with an increase in major ischemic cardiovascular events among patients with type 2 diabetes mellitus and established coronary artery disease.
Conclusions-Among patients with type 2 diabetes mellitus and coronary artery disease in the BARI 2D trial, neither on-treatment nor propensity-matched analysis supported an association of rosiglitazone treatment with an increase in major ischemic cardiovascular events. 10
Mitochondrial DNA Damage Can Promote Atherosclerosis Independently of Reactive Oxygen Species Through Effects on Smooth Muscle Cells and Monocytes and Correlates With Higher-Risk Plaques in Humans
Summary-Damage to mitochondria, the powerhouse of the cell, has been found in human atherosclerosis and is associated with increased levels of free radicals and oxidative stress. Indeed, to date, it has been thought that free radicals mediate almost all of the effect of mitochondrial DNA (mtDNA) damage in atherosclerosis. We show that mtDNA damage occurs early in atherosclerosis in both the vessel wall and circulating cells and is sufficient to cause mitochondrial dysfunction. Using mice, we show that mtDNA damage directly promotes atherosclerosis and features of unstable plaques independently of oxidative stress. mtDNA damage inhibits cell proliferation, promotes cell death, and increases the proinflammatory activity of monocytes. Using virtual histology intravascular ultrasound, we show that mtDNA damage is associated with higher-risk plaques in patients, is independent of other risk factors, and decreases after treatment in patients with acute coronary syndrome. Thus, mtDNA damage in the vessel wall and circulating cells is widespread and causative, indicates higher risk in atherosclerosis, and can promote disease independently of oxidative stress. mtDNA damage may be useful as a biomarker for high-risk atherosclerosis, and protection against mtDNA damage and improvement in mitochondrial function are potential areas for new therapeutics.
Conclusions-We show that mtDNA damage in vessel wall and circulating cells is widespread and causative and indicates higher risk in atherosclerosis. Protection against mtDNA damage and improvement of mitochondrial function are potential areas for new therapeutics. 11
Mechanically Unloading the Left Ventricle Before Coronary Reperfusion Reduces Left Ventricular Wall Stress and Myocardial Infarct Size
Summary-Each year, nearly 8 million people worldwide suffer a heart attack, which is commonly caused by a blocked coronary artery leading to reduced oxygen supply to the heart, known as ischemia. Every minute of occlusion directly correlates with ongoing heart muscle damage. Treatment focuses on quickly re-establishing blood flow to the heart, known as reperfusion. However, despite timely reperfusion, ≈5% to 10% of patients die in the hospital, and 25% develop chronic heart failure. Using a porcine model of an acute heart attack, we studied whether first reducing the workload of the heart with a mechanical pump despite delaying coronary reperfusion would reduce myocardial damage. We identified that a percutaneously delivered left atrial-to-femoral artery circuit driven by a centrifugal pump reduces left ventricular wall stress, work, and strain while maintaining systemic arterial pressure. Next, we observed that mechanically unloading the heart despite delaying reperfusion promotes phosphorylation of proteins involved in myocardial salvage. Finally, we showed that compared with controls, myocardial damage was reduced with initiation of mechanical support in the setting of a heart attack. These findings suggest that initially reducing the workload of the heart despite delaying coronary reperfusion reduces myocardial injury. The clinical implications of these findings require further study.
Conclusions-These data support that first unloading the left ventricle despite delaying coronary reperfusion during an acute MI reduces myocardial injury. 12
Perivascular Adipose Tissue Potentiates Contraction of Coronary Vascular Smooth Muscle: Influence of Obesity
Summary-Adipose tissue normally surrounds the major conduit coronary arteries on the surface of the heart. The volume of this perivascular adipose tissue (PVAT) expands with obesity and has been shown to be a strong independent predictor of e436 Circulation April 8, 2014
coronary atherosclerosis. Recent studies implicate PVAT as a ready source of vasoactive factors and inflammatory mediators capable of influencing vasomotor function; however, the vascular effects of coronary PVAT have not been clearly defined. Data from this investigation provide novel evidence that coronary PVAT is capable of releasing factors that initiate/potentiate contraction of coronary arteries independently of the effects on the endothelium. Importantly, the vascular influence of PVAT is specific to anatomic location and is augmented in the setting of obesity. Our findings support that this augmented effect of PVAT is related to alterations in Rho-dependent signaling, increased functional expression of Ca V 1.2 channels, or diminished or altered activity of K + channels in obese coronary arteries. Marked alterations in the expression profile of the coronary PVAT proteome in the setting of obesity uncover new potential therapeutic target proteins (eg, calpastatin) and signaling pathways that may contribute not only to the regulation of vascular smooth muscle tone but also to the initiation of smooth muscle differentiation and proliferation observed in obesity-induced cardiovascular disease.
Conclusions-Vascular effects of PVAT vary according to anatomic location and are influenced by an obese phenotype. Augmented contractile effects of obese coronary PVAT are related to alterations in the PVAT proteome (eg, calpastatin), Rho-dependent signaling, and the functional contribution of K + and Ca V 1.2 channels to smooth muscle tone. 13
Serum Proprotein Convertase Subtilisin/ Kexin Type 9 and Cell Surface Low-Density Lipoprotein Receptor: Evidence for a Reciprocal Regulation
Summary-We show novel posttranscriptional regulatory mechanisms determining serum levels and function of proprotein convertase subtilisin/kexin type 9 (PCSK9): clearance via the low-density lipoprotein (LDL) receptor (LDLR) and transport on LDL in a quantitatively significant but less active form. Although PCSK9 is known to regulate LDLR levels, we report here that the reverse is also true and that the main exit route for serum PCSK9 is via LDLR. Thus, LDLR mutations may have larger effects on LDL metabolism if they affect not only LDL internalization but also PCSK9 clearance. We foresee a clinical scenario in which LDLR mutations that affect PCSK9 clearance in addition to LDL clearance (eg, receptor negative) can aggravate hypercholesterolemia via the effect of accumulated PCSK9, resulting from defective clearance, on the normal LDLR allele product. Along this line of thinking, it is also possible to forecast hypercholesterolemia resulting from an LDLR mutation that only causes defective PCSK9 clearance. It is interesting that carriers of LDLR-negative mutations have indeed been reported to show significantly higher LDL levels compared with carriers of dysfunctional LDLR mutations. Our finding that about one third of serum PCSK9 is part of LDL and is in a monomeric, less active form suggests that peripheral distribution and function of this regulator of LDLR levels are influenced by the lipoprotein that acts as a canonical ligand for LDLR. Maneuvers that increase the PCSK9 content of LDL in serum may allow us to broaden the search for inhibitory strategies of PCSK9 action, currently limited to blocking the interaction between PCSK9 and LDLR via antibodies.
Conclusions-Our results support a scenario in which LDLR represents the main route of elimination of PCSK9 and a reciprocal regulation between these 2 proteins controls serum PCSK9 levels, hepatic LDLR expression, and serum LDL levels. 14
Myocardial Injury After Noncardiac Surgery and its Association With Short-Term Mortality
Summary-Perioperative adverse cardiovascular events are the leading cause of morbidity and mortality after noncardiac surgery. Despite efforts to prevent the occurrence of such events, the incidence of postoperative myocardial infarction is still high. To identify patients at risk for postoperative myocardial infarction, measuring cardiac troponin routinely after noncardiac surgery has been suggested. Therefore, in our hospital we implemented routine troponin measurement monitoring on the first 3 days after surgery as part of our standard postoperative care in patients aged ≥60 years undergoing intermediate-to high-risk surgery. This observational cohort study estimated the incidence of myocardial injury after noncardiac surgery and its predictive value on the risk of death within 30 days with the use of data from routine postoperative monitoring of troponin. Postoperative myocardial injury as detected by troponin elevation was found in 19% of the patients, and overall all-cause death within 30 days occurred in 3% of the patients. Although only a minority (<10%) of the patients had typical signs of myocardial ischemia or ECG changes, we found a strong association between postoperative myocardial injury and death. We therefore conclude that patients at risk for early death after noncardiac surgery are easily identified by routine postoperative troponin measurements. Furthermore, the time interval between troponin elevation and death potentially allows physicians to modify prognosis. Implementation of postoperative monitoring of troponin as standard of care is feasible and may improve risk stratification and reclassification of patients at risk for early postoperative death.
Conclusions-Postoperative myocardial injury is an independent predictor of 30-day mortality after noncardiac surgery. Implementation of postoperative troponin monitoring as standard of care is feasible and may be helpful in improving the prognosis of patients undergoing noncardiac surgery. 15
Bayesian Methods Affirm the Use of Percutaneous Coronary Intervention to Improve Survival in Patients With Unprotected Left Main Coronary Artery Disease
Summary-The 2011 American College of Cardiology Foundation/ American Heart Association revascularization guidelines have assigned a Class IIa recommendation ("should be considered") to percutaneous coronary intervention (PCI) to improve survival over medical therapy in selected patients with unprotected left main coronary artery disease, yet no trials have directly compared PCI with medical therapy for patients with this condition. We used traditional frequentist statistical approaches and bayesian methods to analyze the 7 trials comparing coronary artery bypass graft surgery with medical therapy and 12 clinical trials comparing coronary artery bypass graft with PCI for patients with unprotected left main coronary artery disease. The odds ratio (OR) for 1-year mortality after PCI versus coronary artery bypass graft using bayesian meta-analysis (posterior median OR, 1.04, 95% bayesian credible interval [BCI], 0.74-1.39) was not different from the OR using frequentist random-effects meta-analysis (OR, 1.00; 95% confidence interval, 0.72-1.40). A bayesian cross-design analysis suggested that the primary outcomes were similar for randomized clinical trials (OR, 0.99; 95% BCI, 0.67-1.43), matched cohort studies (OR, 1.10; 95% BCI, 0.76-1.73), and other types of cohort studies (OR, 0.93; 95% BCI, 0.58-1.35). A bayesian network meta-analysis suggested that medical therapy alone is associated with a higher 1-year mortality than PCI for patients with unprotected left main coronary artery
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Coronary Heart Disease in 2013 e437 disease (OR, 3.22; 95% BCI, 1.96-5.30). Bayesian methods support the current revascularization guidelines and suggest that PCI improves survival over medical therapy alone for patients with unprotected left main coronary artery disease. An integrated approach using both frequentist and bayesian methods may yield new insights to enhance the translation of trial data into clinical practice.
Conclusions-Bayesian methods support the current guidelines, which were based on traditional statistical methods and have proposed that PCI, like CABG, improves survival for patients with unprotected left main coronary artery disease compared with medical therapy. An integrated approach using both direct and indirect evidence may yield new insights to enhance the translation of clinical trial data into practice. 16
Should Bilateral Internal Thoracic Artery Grafting Be Used in Elderly Patients Undergoing Coronary Artery Bypass Grafting?
Summary-Our study shows that long-term survival after bilateral internal thoracic artery (BITA) grafting with the skeletonization technique is good for all age groups (≤65, 65-75, >75 years), approaching survival of the sex-and age-matched general population. Despite significantly lower long-term survival in the older age group (>75 years), their survival benefit, compared with Charlson Comorbidity Index-predicted survival without surgery, was not lower than that of the younger age groups. In our opinion, BITA grafting should be considered in patients >65 years of age because of the significant survival benefit, with no increased risk of sternal infection. This observation supports increased adoption of BITA grafting in the elderly, who are beginning to constitute a large proportion of the patients referred today for coronary artery bypass grafting. A major concern of surgeons that discourages them from the use of BITA is postoperative sternal infection, especially in elderly patients, who have poor sternal blood supply. The present study showed that the risk of sternal infection was not increased in the older age group; thus, age alone should not preclude the use of BITA. This observation is probably related to better preservation of sternal collateral blood flow with the skeletonization technique. The reduction of sternal infection occurrence in the later period of our study (2000) (2001) suggests that the use of BITA grafting should be selective and that this technique should not be used in patients with chronic obstructive pulmonary disease or in obese females who have diabetes mellitus.
Conclusions-Bilateral internal thoracic artery grafting should be considered in patients >65 years of age because of the significant survival benefit obtained with this surgical technique with no additional risk of sternal wound infection related to age. 17
Prolyl Hydroxylase Domain Protein 2 Plays a Critical Role in Diet-Induced Obesity and Glucose Intolerance
Summary-Obesity is associated with low-grade chronic inflammation, dysregulated adipocytokine production, and increased oxidative stress in visceral adipose tissue, which is believed to result in insulin resistance, high blood pressure, and acceleration of atherosclerosis. Although hypoxia has long been known to reduce body weight in both humans and animals, the role of the hypoxia response system, including hypoxia-inducible factor and an oxygen sensor, prolyl hydroxylase domain protein (PHD), in the regulation of fat mass and glucose metabolism remains controversial. Therefore, in the present study, we sought to determine whether deletion of PHD2, a main isoform of PHD, in adipose tissue affects high-fat diet-induced obesity and glucose intolerance.
We showed that PHD2 deficiency in adipocyte resulted in upregulation of hypoxia-inducible factor and attenuated high-fat diet-induced body weight gain and glucose intolerance compared with control mice. These effects seemed to be mediated by upregulation of glycolytic enzymes in white adipose tissue and uncoupling protein-1 in brown adipose tissue in the PHD2-deficient mice. The PHD2-deficient mice also showed modest improvement in insulin sensitivity. The improvement in glucose metabolism is associated with a decrease in adipocyte size, macrophage infiltration, and abnormal angiogenesis of white adipose tissue in the PHD2-deficient mice. Because of the worldwide pandemic of obesity and diabetes mellitus, a novel strategy that is effective for the treatment of both conditions has been sought. The present study suggests that PHD2 inhibition in adipocyte may be a new therapeutic approach to reduce body weight and to improve glucose tolerance simultaneously.
Conclusions-PHD2 in adipose tissue plays a critical role in the development of diet-induced obesity and glucose intolerance. PHD2 might be a novel target molecule for the treatment of obesity and associated metabolic abnormalities. 18
Plasma Retinol-Binding Protein 4 (RBP4) Levels and Risk of Coronary Heart Disease: A Prospective Analysis Among Women in the Nurses' Health Study
Summary-Evidence from animal experiments has clearly demonstrated a causal role of retinol-binding protein 4 (RBP4), a cytokine secreted by adipocytes and hepatocytes, in the origin of insulin resistance. Although emerging data from human studies also suggest a link between this molecule and glucose intolerance, as well as many other cardiovascular risk factors, prospective studies examining RBP4 levels in relation to coronary heart disease (CHD) are few. With recent advances in the methodology of measuring RBP4 levels, investigators are now able to distinguish different forms of RBP4 that may have various biological activities and thus are likely associated with CHD risk differentially. Using data from the wellcharacterized female Nurses' Health Study, we measured full-length and truncated forms of RBP4 and prospectively evaluated their associations with CHD risk in a nested case-control study. We found an interesting temporal pattern in the associations under investigation. After multivariate adjustment of established CHD risk factors, levels of the full-length RBP4 were significantly associated with elevated risk of CHD during the first 8 years of follow-up, whereas this association was gradually attenuated thereafter. The truncated forms of RBP4 were not associated with CHD in this investigation, and no temporal pattern was observed for these forms. These novel data support the notion that the full-length RBP4 is the most biologically active form predicting future CHD events, although future studies are warranted to corroborate the temporal pattern of this association documented in the present study.
Conclusions-In this cohort of women, higher circulating full-length and total RBP4 levels were associated with increased risk of CHD in a time-dependent fashion. Additional data are warranted to confirm the present findings. 19
Long-Term Survival and Repeat Coronary Revascularization in Dialysis Patients After Surgical and Percutaneous Coronary Revascularization With Drug-Eluting and Bare Metal Stents in the United States
Summary-Dialysis patients are at high risk for cardiovascular morbidity and mortality. Although coronary artery revascularization e438 Circulation April 8, 2014
procedures are frequently performed in this high-risk population, clinical trials comparing the outcomes of coronary artery bypass graft surgery or percutaneous coronary intervention have never been performed in dialysis patients. In this study, observational data from the United States Renal Data System are presented on survival after surgical and percutaneous coronary revascularization. Among dialysis patients undergoing coronary revascularization, in-hospital mortality was higher for coronary artery bypass graft patients, but long-term survival was superior with internal mammary grafts. In-hospital mortality was lower for patients who received drug-eluting stents, but the probability of repeat revascularization was higher. Clinical decisions on coronary revascularization in dialysis patients should be individualized.
Conclusions-Among dialysis patients undergoing coronary revascularization, in-hospital mortality was higher after coronary artery bypass grafting, but long-term survival was superior with internal mammary grafts. In-hospital mortality was lower for DES patients, but the probability of repeat revascularization was higher and comparable to that in patients receiving a bare metal stent. Revascularization decisions for dialysis patients should be individualized. 20
Outcomes After Acute Myocardial Infarction in HIV-Infected Patients: Analysis of Data From a French Nationwide Hospital Medical Information Database
Summary-After more than 2 decades of the AIDS epidemic, the spectrum of HIV-associated vascular diseases has evolved considerably. Now that patients have better life expectancy, it has been found that they are more likely than the population at large to experience premature cardiovascular diseases such as acute myocardial infarction. This excess risk may be the consequence of HIV infection, antiretroviral therapies, or other factors. The pathophysiology of this accelerated process is complex and multifactorial and may potentiate the impact of traditional cardiovascular risk factors. The analysis of this large nationwide hospital database, using a matching method, confirmed in a population of acute myocardial infarction patients receiving antiretroviral therapies in a developed country that HIV-infected patients share the same short-term and 1-year mortality as uninfected patients. However, in the year after acute myocardial infarction, HIV-infected patients experience an increased risk of hospitalization for heart failure (odds ratio, 2.82; 95% confidence interval, 1.32-6.01). Despite several study limitations, our study showed that the occurrence of acute myocardial infarction in a population infected with HIV was often associated with asymptomatic cardiac dysfunction and increased incidence of symptomatic heart failure after acute myocardial infarction. Prospective studies are needed to better understand the potential impact of treatment adherence, as well as management of risk factors in secondary cardiovascular prevention.
Conclusions-The present study demonstrates that after acute myocardial infarction, HIV status influences long-term risk, although the short-term risk in HIV patients is comparable to that in uninfected patients. 21
Ten-Year Incidence of Chagas Cardiomyopathy Among Asymptomatic Trypanosoma cruzi-Seropositive Former Blood Donors
Summary-This study presents the results from a large, retrospective cohort study of Chagas cardiomyopathy incidence from a National Heart, Lung, and Blood Institute-funded multicenter study in Brazil.
After an average follow-up of 11 years, cohorts of previously healthy
Trypanosoma cruzi-seropositive and -seronegative blood donors were subjected to comprehensive cardiology evaluations. We estimated a cardiomyopathy incidence of 1.85 per 100 person-years attributable to T cruzi infection. These results are important on several levels. First, in terms of knowledge about the pathogenesis of Chagas disease, we present well-controlled data on cardiomyopathy incidence among previously asymptomatic T cruzi seropositives. Previous studies have relied on case series derived from referral centers, so our incidence estimates better represent those of seropositives in the general population. Second, the inclusion of T cruziseronegatives as control subjects allowed us to validate our screening diagnostic algorithm by estimating the fraction of cardiomyopathy cases resulting from other causes that may be erroneously attributed to Chagas disease. This is important in that endemic countries in Latin America attain living standards that bring with them an increasing incidence of atherosclerotic cardiovascular disease. Third, the data will allow public health authorities to better estimate the potential disease burden and to calculate the costs and benefits of antitrypanosomal treatment in asymptomatic seropositives. Finally, these data will be of interest to the practicing cardiologist in the United States who may increasingly encounter T cruzi-seropositive patients among immigrants from Latin America. They will allow her/him to better estimate prognosis and to better consider treatment.
Conclusions-There is a substantial annual incidence of Chagas cardiomyopathy among initially asymptomatic T cruzi-seropositive blood donors, although disease was mild at diagnosis. 22
Prognostic Significance of Silent Myocardial Infarction in Newly Diagnosed Type 2 Diabetes Mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 79
Summary-In the United Kingdom Prospective Diabetes Study (UKPDS), ≈1 in 6 patients with newly diagnosed type 2 diabetes mellitus had evidence of a silent myocardial infarction (SMI), defined as Q waves on a 12-lead resting ECG in the absence of a history of typical cardiac symptoms. SMI was associated independently with a 58% increased rate of subsequent fatal MI and a 31% increased all-cause mortality rate. Although SMI at diagnosis occurred more often in women, the associated increased rate of a subsequent fatal MI was independent of sex. Some cardiovascular risk factors, including hypertension and microalbuminuria, were more prevalent among patients with SMI. The associations of SMI with increased rates of subsequent fatal MI and all-cause mortality argue for prompt review of the adequacy of management of modifiable cardiovascular risk factors in type 2 diabetes mellitus, but the incremental predictive value of SMI when added to current UKPDS Risk Engine variables (age at diagnosis, sex, ethnicity, smoking, hemoglobin A 1c , systolic blood pressure, and ratio of total to high-density lipoprotein cholesterol) is marginal.
Conclusions-About 1 in 6 UKPDS patients with newly diagnosed type 2 diabetes mellitus had evidence of SMI, which was independently associated with an increased risk of fatal MI and all-cause mortality. However, identification of SMI does not add substantively to current UKPDS Risk Engine predictive variables. 23
Mild Renal Dysfunction and Metabolites Tied to Low HDL Cholesterol Are Associated With Monocytosis and Atherosclerosis
Summary-Patients with chronic kidney disease have a markedly increased risk of atherosclerotic cardiovascular disease. The number of circulating monocytes and their differentiation into lipid-laden macrophages in the arterial wall are fundamental factors involved in plaque formation. In small studies of patients with end-stage renal disease, total monocyte counts and certain monocyte subsets are increased cross-sectionally compared with healthy control subjects, and specific subsets are associated with cardiovascular events and mortality in end-stage renal disease and chronic kidney disease. In a large population-based cohort, we now report in >4500 individuals the novel finding that mild renal dysfunction measured by cystatin C is strongly and independently associated with monocytosis at baseline. We also demonstrate that low high-density lipoprotein cholesterol and amino acid metabolites tied to low high-density lipoprotein cholesterol are independently associated with the monocytosis of mild renal dysfunction, and we show a strong relationship of monocyte count with carotid intima-media thickness, which suggests a direct mechanism of accelerated atherogenesis in mild renal dysfunction. The ability of high-density lipoprotein to stimulate removal of cholesterol from macrophages, "cholesterol efflux," is thought to be central to its antiatherogenic mechanism, and in mouse models, the absence of ATP-binding cassette transporters that promote cholesterol efflux leads to proliferation of hematopoietic stem and progenitor cells, myeloid progenitor cells, and blood monocytes in association with accelerated atherosclerosis. High levels of high-density lipoprotein cholesterol suppress myelopoiesis in animal models. In individuals with mild renal dysfunction, lowhigh-density lipoprotein cholesterol may be causally related to defective cholesterol efflux in hematopoietic stem and progenitor cells and myeloid cells, promoting increased monocyte formation and accelerated atherosclerosis.
Conclusions-A low high-density lipoprotein cholesterol, insulin
resistance phenotype occurs in subjects with mild renal dysfunction and is associated with elevated monocytes and atherosclerosis. High blood monocyte counts may represent a previously unrecognized mechanism underlying the strong relationship between cystatin C and cardiovascular risk. 24
Altered Activation of Endothelial Anti-and Proapoptotic Pathways by High-Density Lipoprotein from Patients with Coronary Artery Disease: Role of High-Density Lipoprotein-Proteome Remodeling
Summary-Reduced plasma levels of high-density lipoprotein (HDL) cholesterol are associated with an increased risk of coronary artery disease (CAD). Besides promoting reverse macrophage cholesterol transport, HDL from healthy subjects has been demonstrated to exert other potentially important antiatherogenic effects, such as inhibition of endothelial cell apoptosis. HDL-cholesterol-raising therapies are therefore currently examined as a potential novel strategy to reduce cardiovascular risk. Of note, endothelial dysfunction and injury are thought to play an important role in the progression of CAD. In the present study, however, we demonstrate for the first time that HDL from patients with CAD, in contrast to HDL from healthy subjects, does not activate endothelial antiapoptotic pathways, but rather stimulates potential endothelial proapoptotic signaling pathways. HDL-proteome remodeling, ie, changes in the clusterin and apolipoprotein C-III contents of HDL in patients with CAD, was identified as an important underlying mechanism leading to these altered functional properties of HDL, in particular, with respect to the effects of HDL on endothelial anti-and proapoptotic pathways in patients with coronary disease. These findings provide novel insights into mechanisms leading to altered vascular effects of HDL in coronary disease that at present may be of particular interest, given the interest in HDL-cholesterol raising as a potential therapeutic strategy in patients with CAD.
Conclusions-The present study demonstrates for the first time that HDL CAD does not activate endothelial antiapoptotic pathways, but rather stimulates potential endothelial proapoptotic pathways. HDL-proteome remodeling plays an important role for these altered functional properties of HDL. These findings provide novel insights into mechanisms leading to altered vascular effects of HDL in coronary disease. 25
Percutaneous Coronary Intervention Versus Optimal Medical Therapy for Prevention of Spontaneous Myocardial Infarction in Subjects With Stable Ischemic Heart Disease
Summary-Contemporary studies have shown that spontaneous myocardial infarction (MI) but not periprocedural MI is related to subsequent mortality. In trials in which procedural MI preferentially occurs with higher frequency in one arm, such as percutaneous coronary intervention versus optimal medical therapy trials, the definition and prognostic significance of these biomarker elevations assume significance because the trial interpretation will change on the basis of the frequency of these events. Procedural MI, which occurs at a frequency as high as 50% on the basis of the biomarker tested and the definition used, has the potential to completely change the results of clinical trials. In the present study of patients with stable ischemic heart disease, percutaneous coronary intervention compared with optimal medical therapy alone was associated with significant reduction in the risk of spontaneous non-procedure-related MI at the risk of procedural MI with no difference in all MI, thus suggesting that the interpretation of these trials varies depending on the MI definition used. The present report shows that the point estimate for mortality parallels the prevention of spontaneous MI but not procedural MI, suggesting that spontaneous non-procedure-related MI is prognostically more important, consistent with recently published reports. Further trials are needed to determine whether these associations are causal. If the results of the percutaneous coronary intervention versus optimal medical therapy trials are true (with no difference in MI) and are to be seen in routine clinical practice, postprocedure marker measurement (rarely drawn routinely in the United States) needs to be implemented universally. This only applies if procedural MI is determined to be prognostically important in future studies. 
Conclusions

Targeting GGTase-I Activates RHOA, Increases Macrophage Reverse Cholesterol Transport, and Reduces Atherosclerosis in Mice
Summary-The RHO family proteins undergo posttranslational lipidation by protein geranylgeranyltransferase (GGTase-I). It is widely believed that geranylgeranylation is essential for membrane targeting and activity of the RHO proteins; this notion is supported by numerous studies using statins to reduce prenylation in cells. However, we recently demonstrated that knockout of GGTase-I in macrophages hyperactivates RHOA, RAC1, and CDC42; increases e440 Circulation April 8, 2014 cytokine production; and induces rheumatoid arthritis in mice. In this study, we tested whether the increased inflammatory signaling of GGTase-I-deficient macrophages and the systemic inflammation and rheumatoid arthritis would accelerate atherosclerosis development in low-density lipoprotein receptor-deficient mice. As expected, aortic lesions in mice lacking GGTase-I in macrophages contained significantly more T lymphocytes compared with control. But surprisingly, aortic lesions were markedly reduced. Analyses of GGTase-Ideficient macrophages revealed reduced foam cell formation and a striking increase in basal and high-density lipoprotein-stimulated cholesterol efflux, which resulted in increased levels of macrophagestimulated reverse cholesterol transport in vivo. The increased cholesterol efflux of GGTase-I-deficient macrophages was caused by RHOA-mediated upregulation of cyclooxygenase 2-peroxisome proliferator-activated receptor-γ signaling, which resulted in increased expression of the scavenger receptors SR-B1 and CD36. The results are clinically relevant in that they demonstrate a potent antiatherogenic effect of blocking prenylation in the face of inflammation and rheumatoid arthritis, diseases that normally carry increased risks of atherosclerosis. Moreover, reduced prenylation of RHO proteins is frequently cited as a mechanism for the antiatherogenic properties of statins.
Conclusions-Targeting
GGTase-I activates RHOA and leads to increased macrophage reverse cholesterol transport and reduced atherosclerosis development despite a significant increase in inflammation. 27
Reduction in First and Recurrent Cardiovascular Events With Ticagrelor Compared With Clopidogrel in the PLATO Study
Summary-We sought to evaluate the effect of potent platelet inhibition after acute coronary syndrome on total (ie, first and recurrent) occurrences of any of cardiovascular event. In the PLATelet inhibition and patient Outcomes (PLATO) study involving 18 624 patients, treatment with the more potent agent ticagrelor, as compared with clopidogrel, reduced not only the first occurrence but also repeated cardiovascular events. Ticagrelor treatment is associated with a slightly increased risk of having a first non-coronary artery bypass graft major bleed but, thereafter, the bleeding risk is similar to clopidogrel despite continuing unchanged long-term treatment. Clinically, these results have important implications for guiding physicians to continue ticagrelor therapy, rather than changing therapy to alternative agents, even for patients who may experience an event while on treatment.
Conclusions-In PLATO, treatment with ticagrelor compared with clopidogrel resulted in a reduction in total events, including first and subsequent recurrent cardiovascular events, when compared with clopidogrel. These types of analyses demonstrate an even greater absolute benefit of ticagrelor over clopidogrel than previously reported. 28
Novel Insights Into the Critical Role of Bradykinin and the Kinin B2 Receptor for Vascular Recruitment of Circulating Endothelial Repair-Promoting Mononuclear Cell Subsets: Alterations in Patients With Coronary Disease
Summary-Endothelial injury is considered critical for initiation and progression of atherosclerosis and its clinical complications in coronary artery disease. Coronary atherosclerotic plaque erosion with the loss of an intact endothelial cell layer is thought to represent a relevant cause of acute coronary syndromes. The endothelial cellsupportive effects of bradykinin, an endothelial cell-derived vasoactive peptide, and the kinin B 2 receptor (B 2 R) have mainly been attributed to their actions on local endothelial cells. In the present study, we newly report that bradykinin and its B 2 R receptor promote selective recruitment and functional activation of B 2 R-expressing circulating mononuclear cell subsets at sites of endothelial injury, which support endothelial repair after arterial injury in a paracrine manner. Notably, in patients with coronary artery disease, B 2 R downregulation leads to a dysfunctional bradykinin-dependent endothelial repair response by these circulating endothelial repairpromoting cell types, representing a potential novel mechanism promoting progression of endothelial injury in patients with coronary artery disease. Moreover, ex vivo B 2 R-overexpression rescued the impaired capacity of these cells from patients with coronary artery disease to promote endothelial repair. It will therefore be of interest to explore approaches to restore B 2 R expression in future studies. In summary, the present study identifies a novel mechanism likely promoting an impaired capacity for endothelial repair in patients with coronary disease, involving a reduced B 2 R expression on circulating endothelial repair supporting cell populations leading to their reduced recruitment to sites of arterial injury and likely an impaired capacity for endothelial repair.
Conclusions-We newly report that bradykinin/B2R signaling may promote endothelial repair after arterial injury by selective recruitment and functional activation of B2R-expressing circulating mononuclear cell subsets. In CAD patients, B2R downregulation on endothelial repair-promoting circulating mononuclear cells substantially impairs the bradykinin-dependent endothelial repair, representing a novel mechanism promoting endothelial injury in CAD patients. 29 
